<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01743222</url>
  </required_header>
  <id_info>
    <org_study_id>Cx621-0101</org_study_id>
    <nct_id>NCT01743222</nct_id>
  </id_info>
  <brief_title>Intralymphatic eASC Administration in Healthy Volunteers</brief_title>
  <official_title>Cx621-0101 Phase I Clinical Trial in Healthy Volunteers to Evaluate the Feasibility and Safety of the Intralymphatic Administration Technique of Expanded Allogeneic Adipose-derived Stem Cells (eASCs)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tigenix S.A.U.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to determine the safety, tolerability and feasibility of the inguinal&#xD;
      intralymphatic administration of expanded allogeneic adipose-derived stem cells (eASCs)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase I, unicentric, single blind, clinical trial with healthy volunteers to determine the&#xD;
      feasibility of a new administration technique.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local and systemic reaction to administration procedure</measure>
    <time_frame>29 days</time_frame>
    <description>Pain in administration area will be assessed by a visual analogical scale.&#xD;
Medical exploration of the administration area will be performed to identify any skin reaction.&#xD;
Inguinal scan will be performed to assess any lymphatic node modification.&#xD;
Systemic tolerability will be measured by number of AE (Adverse Event) recorded at any time, including any alteration in laboratory parameters and/or physical exploration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic parameters</measure>
    <time_frame>29 days</time_frame>
    <description>Detection of reactive cells and antibodies against eASC&#xD;
Lymphocyte subpopulations studies</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Localized Adverse Reaction to Administration of Drug</condition>
  <arm_group>
    <arm_group_label>eASC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>eASC&#xD;
First cohort (3 volunteers, first volunteer is not randomized to detect any acute reaction): injection of 2.5 millions of eASCs suspended in 0.25 ml of HTS per lymph node, total dose 5 millions of cells.&#xD;
Second cohort (3 volunteers, first volunteer is not randomized to detect any acute reaction): injection of 5 millions of eASCs suspended in 0.5 ml of HTS per lymph node, total dose 10 millions of cells.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>First cohort (2 volunteers): injection of 0.25 ml of Hypo Thermosol (HTS) per lymph node&#xD;
Second cohort (2 volunteers): injection of 0.5 ml of Hypo Thermosol (HTS) per lymph node</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>eASC</intervention_name>
    <description>First cohort: Intra lymph node injection of 2.5 millions of eASCs suspended in 0.5 ml of HypoThermosol per lymph node, total dose 5 millions of cells.&#xD;
Second cohort: Intra lymph node injection of 5 millions of eASCs suspended in 0.25 ml of HypoThermosol per lymph node, total dose 10 millions of cells.</description>
    <arm_group_label>eASC</arm_group_label>
    <other_name>Allogenic Stem Cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>First cohort (2 volunteers): injection of 0.25 ml of HypoThermosol (HTS) per lymph node&#xD;
Second cohort (2 volunteers): injection of 0.5 ml of HypoThermosol (HTS) per lymph node</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>HypoThermosol HTS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 18 and 55 both included&#xD;
&#xD;
          -  Inform Consent Form signed&#xD;
&#xD;
          -  Body Mass Index (BMI) between 19 and 29 kg/m2&#xD;
&#xD;
          -  Presence of, at least, one lymph node of 1cm in its larger diameter in each inguinal&#xD;
             location. It has to be accessible for administration after its localization using&#xD;
             ultrasound scan.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant (positive to urine pregnancy test) or breastfeeding women.&#xD;
&#xD;
          -  Subjects with history of any organic or psychic pathology in their records, physical&#xD;
             exploration or any complementary test.&#xD;
&#xD;
          -  Any relevant current pathology, including cancer, liver pathology, gastrointestinal&#xD;
             dysfunction, renal alteration, respiratory pathology or active acute infectious&#xD;
             problems.&#xD;
&#xD;
          -  Chronic disorders or previous recurrent like hypertension, infections, cardiovascular,&#xD;
             respiratory, endocrine, neurologic, hematologic, renal or liver disorders.&#xD;
&#xD;
          -  Subjects treated four weeks before the first administration with any drug, medicinal&#xD;
             plant or Consumer Health Care in a continue routine. It is not consider exclusion&#xD;
             criteria a sporadic medication. The physician will study the interaction between the&#xD;
             eASC with this medication.&#xD;
&#xD;
          -  History of hypersensibility to drugs.&#xD;
&#xD;
          -  Volunteers participants in other clinical trial within 4 months prior the start of the&#xD;
             study.&#xD;
&#xD;
          -  Blood or derivatives transfusion in 6 months before the trial.&#xD;
&#xD;
          -  Known history of abuse of alcohol or other addictive substances(amount of alcohol&#xD;
             allow as maximum in this trial is 0.5 liter of wine or two beers or amount in grams&#xD;
             equivalent to this of any other alcoholic drink).&#xD;
&#xD;
          -  Illegal drugs consumption during the month before the enrollment in the study or&#xD;
             positive result to a drug test.&#xD;
&#xD;
          -  Positive serology for B hepatitis virus (HbsAg), C hepatitis virus or HIV (Human&#xD;
             Inmunodeficiency Virus).&#xD;
&#xD;
          -  Subjects whose freedom depends on legal or administrative requirements.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Belén Sádaba, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unidad de Investigación Clínica de la Clínica Universidad de Navarra</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Unidad de Investigación Clínica de la Clínica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>August 24, 2012</study_first_submitted>
  <study_first_submitted_qc>December 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2012</study_first_posted>
  <last_update_submitted>April 10, 2019</last_update_submitted>
  <last_update_submitted_qc>April 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

